KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?

Detalles Bibliográficos
Autores principales: Lopez-Crapez, E, Mineur, L, Emptas, H, Lamy, P-J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844033/
https://www.ncbi.nlm.nih.gov/pubmed/20160721
http://dx.doi.org/10.1038/sj.bjc.6605582
_version_ 1782179275180343296
author Lopez-Crapez, E
Mineur, L
Emptas, H
Lamy, P-J
author_facet Lopez-Crapez, E
Mineur, L
Emptas, H
Lamy, P-J
author_sort Lopez-Crapez, E
collection PubMed
description
format Text
id pubmed-2844033
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-28440332011-03-16 KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity? Lopez-Crapez, E Mineur, L Emptas, H Lamy, P-J Br J Cancer Letter to the Editor Nature Publishing Group 2010-03-16 2010-02-16 /pmc/articles/PMC2844033/ /pubmed/20160721 http://dx.doi.org/10.1038/sj.bjc.6605582 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Letter to the Editor
Lopez-Crapez, E
Mineur, L
Emptas, H
Lamy, P-J
KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
title KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
title_full KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
title_fullStr KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
title_full_unstemmed KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
title_short KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
title_sort kras status analysis and anti-egfr therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844033/
https://www.ncbi.nlm.nih.gov/pubmed/20160721
http://dx.doi.org/10.1038/sj.bjc.6605582
work_keys_str_mv AT lopezcrapeze krasstatusanalysisandantiegfrtherapiesiscomprehensivenessabiologistsfancyoraclinicalnecessity
AT mineurl krasstatusanalysisandantiegfrtherapiesiscomprehensivenessabiologistsfancyoraclinicalnecessity
AT emptash krasstatusanalysisandantiegfrtherapiesiscomprehensivenessabiologistsfancyoraclinicalnecessity
AT lamypj krasstatusanalysisandantiegfrtherapiesiscomprehensivenessabiologistsfancyoraclinicalnecessity

Ejemplares similares